ITRM Stock Overview
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Iterum Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$7.05 |
| 52 Week Low | US$0.60 |
| Beta | 1.61 |
| 1 Month Change | 56.99% |
| 3 Month Change | 2.46% |
| 1 Year Change | -76.83% |
| 3 Year Change | -96.20% |
| 5 Year Change | n/a |
| Change since IPO | -99.24% |
Recent News & Updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19
Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Recent updates
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Aug 19Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03
Aug 12Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate
Jul 11Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
May 06Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?
Jan 12Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?
Sep 25Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy
Jul 05It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year
Jun 11Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?
May 20Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Feb 04This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)
Feb 04Iterum Therapeutics shares slide 13% on raising $10M
Feb 03Iterum Therapeutics rises 39% on RA Capital stake disclosure
Dec 03Iterum Therapeutics files US application for sulopenem in urinary tract infections
Nov 30Iterum Therapeutics EPS beats by $0.45
Nov 16Shareholder Returns
| ITRM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.0% | -0.7% | 0.9% |
| 1Y | -76.8% | 4.9% | -10.9% |
Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: ITRM underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| ITRM volatility | |
|---|---|
| ITRM Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ITRM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ITRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 13 | Corey Fishman | https://www.iterumtx.com |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc Fundamentals Summary
| ITRM fundamental statistics | |
|---|---|
| Market Cap | US$17.86m |
| Earnings (TTM) | -US$43.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs ITRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ITRM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.53m |
| Earnings | -US$43.53m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 92.8% |
How did ITRM perform over the long term?
See historical performance and comparison